ERBB2 and breast cancer: Lapatinib is an orally active small molecule, it is a first-generation dual tyrosine kinase inhibitors that reversibly binds EGFR and HER2 [5] that has been approved in combination with capecitabine for the treatment of refractory breast cancer [6].